Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel
2nd March 2026 Uncategorised 0Ascendis Pharma is spiraling upward by way of its TransCon platform. For the third time in six years, the Copenhagen-based biopharma has scored an FDA approval for a rare disease medicine that was developed with its “transient conjugation” drug delivery technology. The FDA has signed off on Yuviwel, a once-weekly injection to treat children with achondroplasia, a genetic disorder that causes dwarfism.
More: Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel
Source: fierce